Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 411 to 420 of 1003 total matches.

In Brief: Toxicity of Gadolinium-Based Contrast Agents

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
Gadolinium-based contrast agents, which are used mainly for magnetic resonance imaging and angiography, were first introduced partly because of the discovery in the 1990’s that iodine-based contrast agents could cause nephrotoxicity and acute renal failure. Some recent reports have suggested, however, that gadolinium-based agents may also be nephrotoxic.1 One patient who developed acute renal failure after use of gadolinium-based contrast had a renal biopsy that showed acute tubular injury.2Moreover, after exposure to gadolinium-based contrast, some patients with severe renal insufficiency,...
Med Lett Drugs Ther. 2007 Jun 4;49(1262):45 |  Show IntroductionHide Introduction

Addendum: Warfarin-Acetaminophen Interaction

   
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008  (Issue 1288)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions”1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect.2Patient susceptibility varies, possibly on a genetic basis; occasional use of acetaminophen generally has little or...
Med Lett Drugs Ther. 2008 Jun 16;50(1288):45 |  Show IntroductionHide Introduction

Varenicline (Chantix) Warnings: Risk Versus Benefit

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008  (Issue 1290)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations of preexisting psychiatric illness associated with its use. Agitation, hostility, depressed mood, suicidal ideation and suicidal behavior have been reported as postmarketing adverse events in patients who took varenicline and stopped smoking and in those who took the drug and continued to smoke.
Med Lett Drugs Ther. 2008 Jul 14;50(1290):53 |  Show IntroductionHide Introduction

ECGs Before Stimulants in Children

   
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008  (Issue 1291)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
The American Heart Association (AHA) recently published a statement saying that it would be reasonable to obtain an electrocardiogram (ECG) in children being evaluated for stimulant drug therapy for attention deficit hyperactivity disorder (ADHD). A subsequent news release in conjunction with the American Academy of Pediatrics provided a clarification, saying that it would be reasonable to consider obtaining an ECG in such children.
Med Lett Drugs Ther. 2008 Jul 28;50(1291):60 |  Show IntroductionHide Introduction

Zingo for Local Analgesia in Children

   
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008  (Issue 1293)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
The FDA has approved the marketing of a new device for delivering lidocaine to the skin of children undergoing a venipuncture or intravenous (IV) line placement. Zingo (Anesiva) is a powder intradermal injection system.
Med Lett Drugs Ther. 2008 Aug 25;50(1293):68 |  Show IntroductionHide Introduction

In Brief: Melamine

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008  (Issue 1297)
Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons ...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware,...
Med Lett Drugs Ther. 2008 Oct 20;50(1297):81 |  Show IntroductionHide Introduction

In Brief: New Propellants for Albuterol Metered-Dose Inhalers

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008  (Issue 1298)
of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York ...
Inhaled drugs for asthma are available in the US mainly in pressurized metered-dose inhalers (MDIs), which require a propellant, and dry powder inhalers, which do not. The chlorofluorocarbon (CFC) propellants in MDIs are being replaced by hydrofluoroalkane (HFA) propellants for environmental reasons: CFCs contribute to the depletion of the ozone layer. December 31, 2008 will be the last day that albuterol MDIs using CFC propellants can be sold in the US. The FDA is expected to announce a termination date for other CFC-containing products in the near future.Three HFA albuterol inhalers and one...
Med Lett Drugs Ther. 2008 Nov 3;50(1298):85 |  Show IntroductionHide Introduction

In Brief: Fluoroquinolones and Tendon Injuries

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any fluoroquinolone, either while the drug is being taken or for up to several months afterwards.Fluoroquinolone-related tendon injury is rare; estimates for its incidence in the general population range from 0.14% to 0.4%. The risk is higher for patients >60 years old and for those taking corticosteroids. For patients with organ transplants, the incidence may be as high as 15%.1 A case-control...
Med Lett Drugs Ther. 2008 Dec 1;50(1300):93 |  Show IntroductionHide Introduction

In Brief: Different Diets

   
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009  (Issue 1308)
of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York ...
A recent article in the New England Journal of Medicine confirms something that others, including The Medical Letter (Treat Guidel Med Lett 2008; 6:23), have been saying for years: no particular combination of protein, carbohydrate and fat in the diet offers any advantage in losing weight. This randomized 2-year trial followed 800 overweight and obese subjects on low fat/average protein, low fat/high protein, high fat/average protein, and high fat/high protein diets. Carbohydrate intake varied from 35% (in the high fat/high protein diet) to 65% (in the low fat/average protein diet). All...
Med Lett Drugs Ther. 2009 Mar 23;51(1308):24 |  Show IntroductionHide Introduction

In Brief: Plan B for 17-Year Olds

   
The Medical Letter on Drugs and Therapeutics • May 18, 2009  (Issue 1312)
. Mukherjee, M.D., F.A.C.C., Yale School of Medicine F. Estelle R. Simons, M.D., University of Manitoba ...
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B, taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception.2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B. Fetal malformations have not been associated with pregnancies that occurred...
Med Lett Drugs Ther. 2009 May 18;51(1312):40 |  Show IntroductionHide Introduction